{"id":"W2602169105","doi":"10.1182/blood-2016-11-750158","title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of Calgary","funders":"National Cancer Institute; Karyopharm Therapeutics","keywords":"Medicine; Internal medicine; Adverse effect; Myeloid leukemia; Population; Hazard ratio; Toxicity; Phases of clinical research; Refractory (planetary science); Oncology; Cancer; Gastroenterology; Confidence interval; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001681637,0.00133576,0.001598293,0.0004135816,0.0003688696,0.0006894884,0.0007160836,0.0009374491,0.004508427],"category_scores_gemma":[0.0007960879,0.000414205,0.000779639,0.000232228,0.0006811019,0.0007132299,0.0002994844,0.002453124,0.000849807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005413977,"about_ca_system_score_gemma":0.0009166333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003147619,"about_ca_topic_score_gemma":0.0009113143,"domain_scores_codex":[0.9996731,0.0001683306,0.00001567888,0.00005695845,0.0000302992,0.00005561848],"domain_scores_gemma":[0.9994696,0.0001026839,0.00009719087,0.00004007079,0.00003468764,0.0002557561],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7273024,0.09204543,0.00535642,0.001103015,0.001015012,0.0004332626,0.0002679982,0.004481825,0.05430934,0.000593839,0.007089153,0.1060022],"study_design_scores_gemma":[0.5097601,0.4737017,0.006846308,0.00003586346,0.0001930981,0.0002541665,0.0000457081,0.002160571,0.004304933,0.0002657131,0.002405299,0.00002643758],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993081,0.00131812,0.0005341314,0.0004363482,0.0001239195,0.002447232,0.0007891543,0.00008799467,0.001182112],"genre_scores_gemma":[0.9887062,0.001322309,0.001807629,0.0007177575,0.0001441656,0.003070865,0.001484771,0.00001624095,0.002730113],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004508427,"threshold_uncertainty_score":0.01508224,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1026217167358261,"score_gpt":0.4179450152060915,"score_spread":0.3153232984702654,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}